Trusopt Ophthalmic Solution contains dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II. Following topical ocular administration, Trusopt reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
Supplied: 10 mL, in an 18 mL capacity bottle.
Dose: The dose is one drop of TRUSOPT Ophthalmic Solution in the affected eye(s) three times daily. The IOP-lowering effect of Trusopt was approximately 3 to 5 mmHg throughout the day and this was consistent in clinical studies of up to one year duration.
The efficacy of Trusopt when dosed less frequently than three times a day (alone or in combination with other products) has not been established.
Children: Safety and IOP-lowering effects of Trusopt have been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-treatment-controlled trial.
Pregnancy: (Category C) TRUSOPT is only recommended for use during pregnancy when benefit outweighs risk.
TRUSOPT may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
Although the risk of serious side effects is low when TRUSOPT is used in the eyes, you should be aware of side effects that can occur if the medication is absorbed into your bloodstream.
Stop using TRUSOPT and call your doctor at once if you have a serious side effect such as:
- swelling or redness of your eyelids;
- eye redness, pain, discomfort, or sensitivity to light;
- drainage, crusting, or oozing of your eyes or eyelids;
- severe skin reaction: fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling; or
- stomach pain, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes).
Trusopt is a sulfonamide and, although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration with Trusopt. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.